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EWects of urodilatin in the rat kidney: Comparison with ANF and
interaction with vasoactive substances. We compared the effects of
urodilatin (URO) and atrial natriuretic factor (ANF) in normal and
hydronephrotic kidneys (HNK) of rats. Furthermore, the impact of
blocking different vasoactive hormones on the action of natriuretic
peptides on vessels of cortical (C) and juxtamedullary (JM) glomeruli was
studied in HNK by using URO. In normal kidneys, effects of URO and
ANF (1.2, 2.4, 4.8, 12, and 19 10 mol kg1 min1 i.v.) were not
significantly different. At 12 lO molkg1 min1, URO and ANF
increased urine flow 5.4 1.7 and 3.0 0.8-fold, increased urinaly sodium
excretion 20.7 8.8 and 10.3 4.0-fold, and decreased blood pressure by
13 2% and 12 1%, respectively (mean SCM). In HNK, URO and
ANF (0.4, 0.9, and 2.0 10_11 mol kg1 min1 i.v. and local application
of 0.5, 1.0, and 2.0 i0 M) dose-dependently dilated preglomerular
vessels (max 20%), constricted efferent arterioles (max 15%), and
increased glomerular blood flow of C glomeruli in an identical fashion.
Comparing URO effects on C and JM arterioles (0.4 and 0.9 10
mol . kg min i.v.), JM responses were about one third of C responses.
Angiotensin converting enzyme inhibition (ACEI, 2 10 mol kg'
quinapril i.v.), combined ACEI and cyclooxygenase inhibition (CYOI,
2.8 iO M indomethacin), and endothelin (ET) receptor blockade (10—6
M BQ 123 and IRL 1038) diminished preglomerular vasodilation (C and
JM) caused by URO infusion. Efferent vasoconstriction (C and JM)
caused by URO was exaggerated by blockade of nitric oxide synthesis
(10—i M L-NAME) and abolished by combined ACEI and CYOI, by
bradykinin receptor blockade (4 i0 M Hoe 140), and by ET blockade.
CYOI attenuated only JM efferent constriction. Our results show that
URO and ANF possess equipotent vascular and similar natriuretic effects
in the rat kidney. The magnitude of preglomerular vasodilation, which is
directly mediated by these peptides, depends on the basal level of
endogenous vasoconstrictors, while efferent vasoconstriction may be me-
diated by the secondary release of ET.
In 1988 urodilatin (URO) was isolated from human urine and
was claimed to be a natriuretic peptide produced by the kidney
itself [1, 2]. More recently, transcripts of the gene for atrial
natriuretic factor (ANF) have indeed been found in the kidney
[3]. URO has four additional amino acids in comparison to ANF
which has been known since 1981 [I• In contrast to ANF, URO
could not be detected in the circulating blood of humans [5]. The
natriuretic potency of both peptides showed some differences in
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humans as well as in animals [6—9], and the physiological role of
both peptides and the adequate stimuli for their release are still
debated [2, 10—12]. Nonetheless, URO has been successfully used
in the clinical treatment of acute renal failure after organ trans-
plantation [13].
Up to now the question is unsolved as to whether the natriuretic
effect of ANF is solely due to inhibition of tubular sodium
reabsorption or whether vascular effects of ANF are either
predominantly or at least partially involved in natriuresis [101.
ANF increases GFR primarily by raising glomerular capillary
hydraulic pressure [14]. An altered ratio of pre- to postglomerular
resistance is responsible for the increase in glomerular pressure
[14—16]. Preglomerular vasodilation and efferent vasoconstriction
of renal vessels by ANF was directly visualized by us [17, 18] and
others [19, 20]. In contrast, ANF dilated only preglomerular
vessels in the juxtamedullary nephron preparation [21] and had no
effect on isolated renal vessels of the rabbit [22].
The biological effects of URO, ANF and brain natriuretic
peptide (BNP) are thought to be mediated by the natriuretic
peptide receptor (NPR) A subtype which uses guanosine
3',5'-cyclic monophosphate (cGMP) as its second messenger
[23, 24]. These peptides have similar NPR binding properties in
the rat and human kidney [25]. Binding of URO or ANF to
vascular smooth muscle results in vasodilation as demonstrated
in preconstricted arcuate arteries [26] and afferent arterioles
[20]. Efferent vasoconstriction, however, is poorly understood.
It was hypothesized that ANF may constrict the efferent
arteriole via secondary release of a constrictor [14, 20]. How-
ever, blockade of angiotensin II receptors and formation, and
of thromboxane and a-adrenergic receptors failed to inhibit
efferent constriction [14, 20]. Vasoconstrictor effects of ANF
are not restricted to the renal vasculature; they were also
observed in the coronary and gastrointestinal circulation [27,
28].
In one part of our present study we compared the natriuretic
effects of URO and ANF in the normal rat kidney and the
vascular effects in the hydronephrotic kidney model, which per-
mits visualization of the vasculature of cortical (C) and juxtamed-
ullary (JM) glomeruli in vivo [29, 30]. In the other part of the study
we explored the interaction of URO with several vasoactive
hormones at C and JM vessels to gain insight into the mechanisms
by which natriuretic peptides induce preglomerular vasodilation
and efferent constriction.
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Table 1. Control values of vessel lumen diameters, GBF, blood pressure, and body weight
Series 1
(N=6)
Series 2
(N=6)
Series 3
(N=5)
Series 4
(N=5)
Arcuate artery
Interlobular artery
C afferent arteriole
C efferent arteriole
JM afferent arteriole
JM efferent arteriole
proximal
distal
proximal
distal
proximal
distal
proximal
distal
proximal
distal
proximal
distal
pm
p.m
pm
pin
pin
pin
pin
p.m
pm
pin
p.m
pm
80.4 10.9
50.0 6.4
32.1 1.9
13.4 0.7
10.4 0.6
8.2 0.5
14.9 0.7
18.6 1.1
71.5 3.6
46.7 2.7
26.4 1.0
13.0 1.1
9.8 0.6
8.1 0.9
15.1 1.2
19.3 1.6
77.8 4.5
56.3 2.9
30.2 1.7
11.4 1.3
9.7 0.9
8.2 0.6
10.0 0.8
14.9 1.3
23.2 0.9
21.9 1.0
41.9 1.7
44.4 1.8
80.0 9.3
44.1 3.1
26.0 1.8
12.0 1.1
11.2 1.1
7.0 0.5
12.6 0.8
15.5 1.7
19.7 2.2
17.4 1.5
31.7 3.1
35.8 4.1
C GBF ni min '
JM GBF ni min1
48.1 10.6 30.4 8.0 29.7 4.3
397.5 39.7
32.7 5.9
312.5 102.2
Blood pressure mm Hg
Body weightg
115.8 2.4
242 16
105.8 2.4
257 8
104.0 5.1
240 11
109.0 2.9
232 8
Data are mean SEM.
Methods
Experiments on hydronephrotic kidneys
Preparation of the hydronephrotic kidney. Experiments were
performed on 58 female Wistar rats weighing 237 23 g (mean
SD). The technique of splitting the rat kidney has been previously
described in detail [29, 301. In brief, ligation of the ureter via a
flank incision was performed during pentobarbital sodium anes-
thesia (Nembutal' 60 mg kg' i.p., Ceva, Bad Segeberg, Ger-
many). The final experiments were performed under thiobutabar-
bital anesthesia (InactinR 100 mg kg' i.p., Byk Gulden,
Konstanz, Germany) two to three months after the induction of
hydronephrosis. Body temperature was maintained at 37.0 to
37.5°C via a heating table, systemic blood pressure was monitored
via a cannula in the left femoral artery, and isotonic saline (50
min) was continuously infused via a cannula placed in the
jugular vein. After exposure of the left hydronephrotic kidney by
a flank incision, the kidney was split along the greater curvature
with a thermal cautely. In the first two series of experiments the
ventral half and in the other series the dorsal half of the kidney
was sutured to a semicircular frame that was attached to the
bottom of a plexiglas bath. in the first two series intravital
microscopy was confined to the outside of the kidney, whereas in
the other series intravital microscopy of the inside of the kidney
allowed us to visualize JM glorneruli [30]. The entry of the renal
hilus into the bath was sealed with silicone grease, and the bath
was filled with an isotonic, isocolloidal solution (HaemaccelR,
Behringwerke, Marburg/Lahn, Germany) maintained at 37°C. A
Leitz Ultropac water immersion objective (UO-55) was combined
with a television system and video recording for intravital micros-
copy. Kidney preparations were allowed to equilibrate in the
tissue bath for at least one hour after the surgical procedure. The
microcirculatory parameters of this preparation have been dem-
onstrated to be stable for more than three hours [18].
Renal vascular segments. Lumen diameter measurements of the
following vessel segments were carried out, the vessels being
identified according to the branching pattern of the vessels from
the selected cortical (C) or juxtamedullary (JM) glomerulus: (1)
proximal arcuate artery (near the interlobar artery), (2) distal
arcuate artery (near the interlobular artery), (3) proximal inter-
lobular artery (near the arcuate artery), (4) distal interlobular
artery (near the afferent arteriole), (5) proximal afferent arteriole
(near the interlobular artery), (6) distal afferent arteriole (at the
narrowest segment before entering the glomerulus), (7) proximal
efferent arteriole (within 50 j.m of the glomerulus), (8) distal
efferent arteriole (near the welling point). To identify JM glomer-
uli we used the length of the unbranched portion of the efferent
arteriole (cf. [30]). C and JM glomeruli fed from the same arcuate
artery were selected for the purpose of comparison.
Glomerular blood flow (GBF). Red blood cell velocity was
determined in the efferent arteriole by a velocity tracking correla-
tor (Model 102B; 1PM Inc., San Diego, CA, USA) [31]. To obtain
GBF, the measured red cell velocity was multiplied by the luminal
diameter of the efferent arteriole and corrected for the Fahraeus
effect [32].
Experimental protocol
in the following, specified concentrations for locally applied
drugs refer to the final concentration of the drug in the tissue
bath. Each protocol started with two control periods separated by
10 minutes. Each protocol was made up of several periods during
which systemic blood pressure, GBF, and vascular diameters were
measured.
Effects of i.v. or locally applied URO and ANFwere compared
in two series.
Series I (N = 6). After two control periods URO (produced by
W. G. Forssmann) was intravenously infused in three periods of
12 minutes each in the following doses: 0.4, 0.9, and 2.0
mol kg1 min' dissolved in isotonic saline at a rate of 5, 14,
and 29 1id min , respectively. Measurements were done 10
minutes after the start of each infusion. Forty minutes after stop
of the third URO infusion a control measurement was performed.
Thereafter URO was added to the tissue bath in increasing
concentrations: 0.5, 1.0, and 2.0 iO M. The kidney was exposed
to each concentration for 12 minutes. Measurements were per-
formed 10 minutes after the addition of each concentration. In
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Table 1. Continued
Series 5
(N =6)
Series 6
(N =6)
Series 7
(N = 7)
Series 8
(N =6)
Series 9
(N =7)
Arcuate artery
Interlobular artery
C afferent arteriole
C efferent arteriole
JM afferent arteriole
JM efferent arteriole
proximal
distal
proximal
distal
proximal
distal
proximal
distal
proximal
distal
proximal
distal
pm
pin
pm
pm
pm
pm
p.m
pm
p.m
pm
pm
pm
66.2 7.2
41.8 1.6
23.8 1.1
13.9 0.8
10.2 0.6
8.4 0.6
14.3 1.1
17.2 1.2
19.7 1.1
15.5 0.9
32.0 2.1
34.4 2.4
75.5 3.9
46.5 2.0
30.0 1.0
14.6 0.7
10.9 0.8
8.0 0.5
12.2 0.6
14.7 0.9
17.7 0.6
15.0 0.5
28.1 2.3
29.3 1.3
65.7 2.2
45.5 1.4
29.7 0.9
15.3 1.0
10.9 0.8
8.4 0.5
10.8 0.8
14.7 0.8
19.9 1.0
17.4 1.5
31.8 3.9
35.2 4.7
72.8 5.0
45.8 2.6
25.7 0.5
15.2 1.6
9.9 0.6
7.1 0.4
14.4 1.4
17.4 1.1
16.3 1.0
13.4 0.8
29.3 2.5
28.6 1.6
57.3 4.1
42.2 3.2
26.1 1.2
12.6 0.6
11.0 0.5
8.5 0.6
15.8 1.5
19.4 0.8
20.5 1.0
17.5 1.0
31.3 2.6
33.4 3.3
C GBF ni min'
JM GBF ni min1
25.6 4.3
315.9 56.7
32.3 3.0
244.4 24.2
33.6 10.3
281.1 46.5
41.2 4.2
211.5 18.7
36.9 8.5
238.3 50.6
Blood pressure mm Hg
Body weight g
107.5 1.7
249 7
113.3 2.8
227 8
106.4 2.6
224 5
104.2 1.5
240 6
121.4 0.9
231 7
Data are mean SEM.
two additional experiments only saline (without URO) was in-
fused at the same rates to exclude unspecific effects of the
infusion.
Series 2 (N = 6). Equimolar amounts of ANF (produced by
W. G. Forssmann) were used with the identical protocol as in
series 1.
Senes 3 (N 5). The effects of i.v. infused URO (0.4 and
0.9 10_11 mol kg min1) on C and JM vessels and GBFwere
examined. Each infusion period lasted 12 minutes. Measurements
were done 10 minutes after the start of each infusion. In two
additional experiments URO was i.v. infused with the identical
protocol as in the clearance experiments (see below). In these
experiments measurements were done 10 and 20 minutes after the
beginning of each infusion period.
In the following six series the impact of blocking several
vasoactive hormones on C and JM effects of URO was studied.
After two control periods the rats were pretreated with:
Series 4 (N = 5). Angiotensin converting enzyme inhibition(ACEI) by i.v. bolus injection of 2 10—6 mol kg' quinapril
(provided by Goedecke-Parke-Davis, Freiburg, Germany) [33],
measurements after 20 and 40 minutes.
Series 5 (N 6). Cyclooxygenase inhibition (CYOI) by local
application of 2.8 iO M indomethacin (Sigma, Deisenhofen,
Germany) into the tissue bath [301, measurements after 15, 30, 45,
and 60 minutes.
Series 6 (N = 6). Combined ACEI and CYOI by local applica-
tion of 2.8 10 M indomethacin 20 minutes after i.v. bolus
injection of 2 10_6 mol kg1 quinapril, measurements before
indomethacin application and 15, 30, 45, and 60 minutes thereaf-
ter.
Series 7 (N = 7). Blockade of nitric oxide (NO) synthesis by
local application of i0— M L-nitroarginine-methylester (L-
NAME, Sigma) [341, measurements after 15, 30, and 60 minutes.
Series 8 (N = 6). Bradykinin B2 receptor blockade by local
application of 4 10—8 M Hoe 140 (provided by Hoechst, Frank-
furt, Germany) [35], measurements after 15, 30, 60, 90, and 120
minutes.
After a stable state was reached, the last measurement in series
4 to 8 was followed by the identical protocol of URO application
as in series 3.
Series 9 (N = 7). Endothelin (ET) ETA and ETB receptor
blockade by local application of 10_6 M BQ 123 and 106 M IRL
1038 (California Peptide Research, Napa, CA, USA), measure-
ments after 15, 30, 45, and 60 minutes. The last period was
followed by the identical protocol of URO infusion (0.4, 0.9, and
2.0• 10—11 mol kg . min') as in series 1. After stop of the
URO infusion the tissue bath solution was exchanged three times
at intervals of 10 minutes to wash out the ET antagonists.
Thereafter, a new control measurement was done (30 mm after
infusion stop), which was followed by i.v. infusion of URO with
the same protocol as before; 10_6 M BQ 123 as well as 106 M IRL
1038 antagonized the ET-1-induced decrease in GBF in the
hydronephrotic kidney (Endlich et al, manuscript submitted).
Clearance experiments
Animal preparation. In 18 female Wistar rats weighing 206 9
g (mean SD) effects of i.v. infusion of URO and ANF on urine
volume flow (V), urinary sodium excretion (UaV), GFR (esti-
mated by creatinine clearance), and blood pressure were mea-
sured. Animals were anesthetized with thiobutabarbital (100
mg kg1 i.p.), placed on a heating table to maintain body
temperature at 37.0 to 37.5°C, and tracheotomized. The jugular
vein was cannulated for intravenous infusion and the femoral
artery was cannulated for registration of systemic blood pressure
and for removal of blood samples. A 0.5 ml bolus was followed by
continuous i.v. infusion of 17 p.1 . min1 isotonic saline containing
1.5 g dl 1 creatinine to reach a plasma creatinine concentration
of about 15 mg dl* The ureters were exposed by a median
abdominal incision and cannulated without touching the kidneys.
The ureter catheters were externalized and the abdominal incision
was closed with clips.
Measurements. Urine from each ureter was collected in 20
minute periods. Urine volume was determined gravimetrically.
Urinary sodium concentration was measured by flame photometry
(FMD 3, Zeiss, Oberkochen, Germany). Creatinine concentration
in urine and plasma was determined with a creatinine analyzer
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(Model 2, Beckman Instruments, Munich, Germany). Creatinine
clearance was calculated from urine volume flow and creatinine
concentrations of plasma and urine.
Experimental protocol. Animals were divided into three groups
(each N = 6). After one hour of equilibration urine was collected
for 200 minutes divided into ten periods. The protocol started
with three control periods (Cl, C2, C3). Then, i.v. infusion of
URO was started in the first group and i.v. infusion of ANF in the
second group. The third group received only saline. During the
five experimental periods (El, E2, E3, E4, E5) the infused
amounts of URO and ANF were as follows: 1.2, 2.4, 4.8, 12, and
19 10_11 mol kg1 min1. The total infusion rate was kept
constant at 17 d - min'. The experimental periods were followed
by two recovery periods (Ri, R2).
Data analysis
All values are presented as mean SEM. Changes in vascular
diameters and GBF are expressed as percentage changes from the
first control values unless otherwise stated. Clearance data are
expressed as relative changes to the third control period (C3).
Analysis of variance and the Bonferroni method for multiple
comparisons were used to test for statistical significance. The
overall significance level was set to P < 0.05.
Results
Experiments on hydronephrotic kidneys
The control values of vessel diameters, GBF, blood pressure,
and body weight are summarized in Table 1. Blood pressure did
not significantly change in any series except for series 6 where it
fell from a control value of 113.3 2.8 mm Hg to 109.2 2.1 mm
Hg after ACEI and CYOI.
Series 1 and 2. Intravenous infusion of URO or ANF induced
preglomerular vasodilation, efferent vasoconstriction, and an in-
crease in GBF in a dose-dependent fashion (Fig. 1). The afferent
arteriole near the glomerulus dilated only slightly. Forty minutes
after stopping the infusion all diameters returned towards their
control values. GBF decreased from 53 9% to 14 13% and
from 47 10% to —7 7% after stopping the infusion of URO
and ANF, respectively. Subsequent local application of URO or
ANF elicited identical vascular effects compared with i.v. infusion
of these peptides. On the whole, the effects of URO and ANF
were not significantly different from each other. In two additional
experiments, the URO infusion was replaced by saline. In both
experiments fluctuations of GBF were less than 5%.
In the following series, vascular segments and GBF of C and JM
glomeruli were studied.
Series 3. Intravenous infusion of URO dose-dependently dilated
preglomerular vessels, constricted efferent arterioles, and in-
creased GBF of JM as well as of C glomeruli (Fig. 2). Vascular
effects of URO were more pronounced in C arterioles.
Series 4. ACEI by quinapril (20 nun after i.v. bolus injection of
2 10—6 mol kg1) resulted in preglomerular vasodilation of C
and JM vessels (Fig. 3). Efferent arterioles were only significantly
dilated at the distal JM site. C GBF rose by 48 13% and JM
GBF by 23 7%. After ACEI, URO was unable to further dilate
preglomerular vessels (Fig. 2). ACEI did not affect efferent
vasoconstriction by URO resulting in a decrease of GBF.
Series 5. CYOI by indomethacin (60 mm after local application
of 2.8- i0 M) induced constriction of all vessels except for the C
afferent arteriole near the glomerulus (Fig. 3). C and JM vessels
were equally sensitive to CYOI and GBF was reduced by the same
amount (—44 3% and —42 5%, respectively). After CYOI,
URO induced preglomerular dilation, which was shifted to larger
vessels, and a significant constriction only at C efferent arterioles
(Fig. 2). Efferent constriction by URO after CYOI appeared to be
enhanced at C glomeruli and to be blunted at JM glomeruli
compared with URO only (series 3). However, no statistical
significance was achieved. While C GBF increased, JM GBF
remained unchanged.
Series 6. CYOI after ACEI did not fundamentally change the
pattern of vasodilation which was obtained by ACEI alone, except
for a pronounced vasoconstriction at distal JM efferent arterioles
(Fig. 3). C GBF increased by 32 8%, while JM GBF decreased
by —29 3%. After this combined ACE! and CYOI, URO
almost completely lost its characteristic pre- and postglomerular
vascular effects (Fig. 2). Only a few preglomerular segments were
slightly dilated. GBF was increased to a similar extent by URO as
without pretreatment.
Series 7. Blockade of NO synthesis (60 mm after local applica-
tion of io— M L-NAME) reduced pre- and postglomerular
diameters of C and JM vessels and decreased C GBF by —51
4% and JM GBF by —54 6% (Fig. 3). After NO synthase
inhibition, URO again dilated the preglomerular vasculature (Fig.
2). However, the constriction of C and JM efferent arterioles
caused by URO was significantly exaggerated in the absence of
NO production. The URO-induced GBF increase was unchanged
by pretreatment with L-NAME.
Series 8. Bradykinin B2 receptor blockade (local application of
4 10_s M Hoe 140) diminished C and JM GBF in a time-
dependent manner, reaching a stable state after about 90 minutes.
C and JM GBF were lowered by —46 2% and —42 5%,
respectively, after 120 minutes as a result of a diameter reduction
of nearly all pre- and postglomerular vessels (Fig. 3). Although
preglomerular vasodilation by URO was preserved after admin-
istration of Hoe 140, efferent vasoconstriction was significantly
blocked (Fig. 2). C and JM GBF were massively increased by
URO under this condition.
Series 9. ETreceptor blockade (60 mm after local application of
106 M BQ 123 and 106 M IRL 1038) dilated pre- and postglo-
merular vessels and increased C and JM GBF by 15 1% and 11
2%, respectively (Fig. 4). Subsequent infusion of URO dilated
preglomerular vessels and increased C and JM GBF dose-depen-
dently. However, efferent vasoconstriction was absent. After wash
out of the ET antagonists vascular diameters and GBF returned to
baseline. In the absence of ET antagonists, the second infusion of
URO constricted efferent arterioles. Furthermore, the preglo-
merular vasodilation by URO was enhanced.
Clearance experiments
The control values of the three treatment groups (saline, ANF,
and URO) are summarized in Table 2. Intravenous infusion of
saline did not result in any significant change of the measured
parameters. Parameters were also not altered during the three
control periods (Cl to C3) and at the three lower rates (1.2, 2.4,
and 4.8 iO mol -kg' min'; El to E3) of infused ANF or
URO (Fig. 5).
ANF and URO infusion significantly increased urine flow 3.0 ±
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Fig. 1. Percent changes of renal vascular diameters and GBF of Cglomeruli in response to iv. infusion (0.4, 0.9, and 2.0 101J mol kg' min') and local
application (0.5, 1.0, and 2.0 i0° M) of Urodilatin (LI) andANF (U). N = 6each, data are mean SEM. < 0.05 vs. control, °P < 0.05 vs. previous
value, P < 0.05 Urodilatin vs. ANF. Preglomerular: (1) arcuate arteries-proximal; (2) arcuate arteries-distal; (3) iriterlobular arteries-proximal; (4)
interlobular arteries-distal; (5) C afferent arterioles-near interlobular arteries; (6) C afferent arterioles-near glomeruli. Postglomerular: (7) C efferent
arterioles-near glomeruli; (8) C efferent arterioles-near welling point.
0.8-fold and 5.4 1.7-fold, respectively, at an infusion rate of
12 i0 mol kg1 min (E4). At this rate, ANF and URO
raised urinary sodium excretion 10.3 4.0-fold and 20.7
8.5-fold, respectively. Also, blood pressure declined significantly
by 12.2 0.8% (ANF) and 13.2 1.6% (URO). GFR tended to
increase by about 20%, but did not change significantly through-
out the experiments. After stopping the infusion (R1-R2) all
values returned to baseline. Though URO effects on urine flow
and on sodium excretion tended to be greater than ANF effects,
URO and ANF effects on all measured parameters were not
significantly different from each other.
In two experiments on hydronephrotic kidneys using the same
infusion protocol for URO as in the clearance experiments, effects
of URO on GBF and vessels were similar to those in series 3. At
4.8 10_li mol kg1 - min' (E3) GBF increased by 14 and 24%
in JM glomeruli and by 21 and 41% in C glomeruli, and was
further increased by the two higher infusion rates.
Discussion
In the clearance experiments, i.v. infused URO and ANF
increased urine volume flow and sodium excretion to a similar
degree with a concomitant fall in blood pressure (Fig. 5). URO
tended to be the more potent natriuretic substance than ANF, but
the effects of both peptides were not significantly different from
each other. At similar high doses of URO and ANF, a comparable
increase in natriuresis was also observed by Abassi et al [81 and
Saxenhofer, Fitzgibbon and Paul in rats [36]. URO and ANF
effects were almost identical in one study [36], while URO was
about two times more potent than ANF in the other study [81.
In humans and dogs, however, URO was consistently found to
be the more potent natriuretic substance compared with ANF [6,
7, 9]. In contrast to ANF, URO is not inactivated by peptidases
from dog kidney cortex membranes [37]. It was therefore argued
that intravenously applied URO may reach intraluminal receptors
0.4 x 10_il rnol • mm1. kg i.V. GBF, .\% 0.5 x 10 mol • t in bath GBF, .X!
+20 +20
+10 78 j +10 7 8
—10 123456 —10 123456
+30 0.9 x 10- mol • mirn1 • k iv.
*
*
+40 t
+20 *
+30 1 x109moI•I1 in bath
12:4s6J I ______ 78 ]** g—1oCt (0 *
* -cC, U
I— * I—
a, a,
+50
. .
-f60 I
÷40 2 x 10" mol • min . kg iv. . I
+30 I -
* ÷40 2 x iO mol• I in bath
78
** 1 2 3 4 5 6 [ILL!
40 mm after infusion stop ¾ *
+20
+10
0 4 56
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Fig. 2. Percent changes of renal vascular
diameters and GBF of C (El, ) and JM (LI, 1111)
glomeruli in response to URO only [0.4 El, )
and 0.9 ( l) JO mol kg'. min' iv.]
and to URO after different pretreatments. Data
are mean SEM. *P < 0.05 vs. pretreatment,
° P < 0.05 vs. URO without pretreatment.
Preglomerular: (1) to (6) cf. Fig. 1; (5') JM
afferent arterioles-near interlobular arteries;
(6') JM afferent arterioles-near glomeruli.
Postglomerular: (7) to (8) cf. Fig. 1; (7') JM
efferent arterioles-near glomeruli; (8') JM
efferent arterioles-near first branching point.
in the collecting duct in sufficiently high concentration to inhibit
sodium reabsorption [6, 7]. While URO was as potent as ANF in
binding to and activating guanylate cyclase of inner medullary
collecting duct cells of the rat kidney in one study [25], it was
about 10-fold less potent in another study using the same prepa-
ration [36].
In the experiments on hydronephrotic kidneys, we observed
preglomerular vasodilation and efferent vasoconstriction in C
vessels during URO or ANF application (Fig. 1). The vascular
efi'ects were identical for URO and ANF and independent of the
mode of application (i.v. or local). This is in agreement with our
previous findings [17, 181 and those of others [19, 201.
Furthermore, URO was also able to dilate JM afferent arte-
rioles and to constrict JM efferent arterioles (Fig. 2). However,
JM diameter changes were only about one third of C diameter
changes. URO changed the diameter of JM afferent and efferent
arterioles by about 5%. Since control diameters of JM efferent
arterioles in our preparation are about twice those in the JM
nephron preparation (32 vs. 16 gm), such small changes could
have been below the optical resolution in the latter preparation.
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act via the same receptors with similar binding affinity and signal
transduction efficacy in vivo.
Interestingly, i.v. infusion of URO or ANFhad already signif-
icant effects on vascular diameters and GBF in the hydronephrotic
kidney at 0.9 10_li mol kg min. In contrast, sodium ex-
cretion as well as blood pressure were not affected at 1.2W lO
mol kg1 min' URO or ANF, and they did not significantly
change until a tenfold higher dose was infused in the clearance
experiments. In the study of Saxenhofer et al on rats, bolus
injection of 10 mol kg URO already increased sodium
excretion about fourfold [36]. These results suggest that the renal
vasculature is sensitive enough to natriuretic peptides to partici-
pate in elevating sodium excretion. While an increase in GFR was
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This could account for the reported lack of efferent constriction by
ANF at 3- io° M in the JM nephron preparation [21]. At the
same concentration, however, afferent arterioles of the JM
nephron preparation were dilated by about 20%. In addition, the
reported lack of efferent constriction could be caused by altered
basal levels of endogenous vasoactive hormones interfering with
URO. In spite of the small effects of URO on JM vessels, increase
in GBF of C and JM glomeruli was very similar. A participation of
medullary blood flow in mediating natriuresis caused by URO
cannot be excluded from our experiments, while the results of two
other studies suggest that medullary blood flow is not primarily
involved [38, 39]. Since URO and ANF possess equipotent
vascular effects in our preparation, both peptides most probably
Fig. 3. Percent changes of renal vascular
diameters and (JBF of C (U) and JM ()
glomemli after different treatments prior to URO
infusion. Data are mean 5EM. < 0.05 vs.
control.
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Fig. 4. Percent changes of renal vascular diame-
ters and GBF of C (LI, U) and JM (P4 [II) glomendi
in response to URO [0.9 (LI, ) and 2.0 (
FEE) 10-11 mol kg min iv.] afterETreceptor
blockade (local application of 106 M BQ 123 and
10-6 M IRL 1038) and after washout of ETantag-
onists. Diameter and GBF changes after ET
receptor blockade and after washout are shown
as percent changes from the first control values.
N = 7; data are mean SEM. +P < 0.05 vs.
control, *D < 0.05 vs. ET receptor blockade or
wash out, °P < 0.05 vs. URO after washout.
Table 2. Control values of urine volume flow (V), urinary sodium
excretion (UNaV), GFR, blood pressure and body weight (during
collection period C3, mean SEM, per kidney)
Treatment
Saline
(N=6)
ANF
(N=6)
URO
(N=6)
V pJmin' 6.1 1.7 4.4 1.2 6.5 3.2
UNaV pmolmin'
GFR ml min1
0.56 0.16
0.88 0.15
0.31 0.16
1.06 0.15
0.52 0.36
0.83 0.08
Blood pressure mm Hg 115.0 1.3 116.7 1.1 113.3 2.5
Body weightg 203 3 208 4 208 4
frequently measured at higher doses, sodium excretion was re-
ported to increase about threefold in spite of unchanged GFR at
lower doses [6, 7, 36]. However, since basal sodium excretion is
less than 1% of the filtered load, an increase of GFR by a few
percent may be sufficient to increase sodium excretion measur-
ably. Presently, measurement of GFR with such a high accuracy is
technically impossible. By micropuncture of end-proximal tubules
Cogan found that ANF increased GFR and solute delivery out of
proximal tubules by the same percentage [40]. Further, if GFR
was kept at control level during ANF application by an aortic
clamp, natriuresis was substantially reduced [40, 41].
It is generally accepted that ANF and perhaps BNP, which are
secreted into the blood, are capable of modulating renal hemo-
dynamics. URO most likely acts as a paracrine hormone, since it
could not be detected in human plasma (detection limit about
0.1 10— 12 M) [5]. URO is synthesized in cells of the connecting
tubule and secreted into the lumen. If URO is also basolaterally
secreted, concentrations of URO in the interstitium might be
sufficiently high to affect the renal vasculature. Presently, how-
ever, the paracrine route by which URO increases sodium excre-
tion is a matter of speculation [12]. Nonetheless, vascular effects
evoked by i.v. infusion of URO are representative for those
natriuretic peptides that bind to NPR-A and NPR-C receptors,
like ANF and BNP.
In the other part of our study we examined the vascular effects
of URO after blockade of several vasoactive hormones that could
possibly interfere with preglomerular vasodilation and efferent
constriction. ACEI and ET receptor blockade revealed a basal
tone of vasoconstriction by angiotensin II (Ang II) and ET (Figs.
3 and 4). However, ACE inhibitors not only block the formation
of Ang II, they also induce an endothelium-dependent vasodila-
tion by the release and the diminished degradation of bradykinin
and by a direct interaction at the bradykinin B2 receptor level or
transduction process [42, 43]. Further, ACE inhibitors increase
angiotensin I levels which could be enzymatically degraded to
angiotensin-(1-7) [441. This peptide may also induce endothelium-
dependent vasodilation [45]. In conclusion, it remains unclear in
the present study to what extent the observed vasodilation after
ACEI is due to inhibition of Ang II formation. A basal constrictor
tone caused by ET in our preparation has also been shown by
using anti-ET-1/3-antibodies [46].
CYOI, blockade of NO synthase, and blockade of bradykinin B2
receptors revealed basal vasodilation by dilating prostaglandins,
by NO release, and bradykinin (Fig. 3). A basal predominance of
dilating prostaglandins are in agreement with our previous obser-
vation of local CYOI [30], whereas systemic CYOI in female
Wistar rats only decreased medullary blood flow [47]. One reason
might be the surgical trauma inherent in the preparation of the
hydronephrotic kidney. CYOI after ACEI only constricted JM
GBF, .%
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efferent arterioles (Fig. 3). Thus, ACE! seems to reduce the basal
level of dilating prostaglandins at all C vessels and at JM afferent
arterioles. After ACEI, vascular effects of CYOI are confined to
JM vessels as observed in the normal kidney of female rats [47]. A
basal release of NO has recently been shown in our preparation
[34] in line with studies in the normal rat kidney [48]. However, a
bradykinin B2 receptor-mediated basal vasodilation, which is
present in the hydronephrotic kidney, seems to be absent in
conscious rats [49].
Preglomerular vasodilation by URO was diminished after
ACEI, combined ACEI and CYOI, and ET receptor blockade
(Figs. 2 and 4). A dependence of the ANF-mediated preglomeru-
lar vasodilation on the presence of vasoconstrictors was also
observed in other studies [15, 20]. As efferent constriction by
URO persisted after ACEI, in agreement with others [14, 20],
URO reduced GBF under this condition. A decrease of renal
blood flow by ANF after ACEI was also demonstrated in a
clearance study on humans [50]. In another study on humans,
ACEI reduced the increase in GFR by ANF [51]. ANF was shown
to elicit an endothelium-independent vasodilation [52]. After
blockade of prostaglandins and NO synthesis URO was still able
to dilate preglomerular vessels (Fig. 2). However, the pattern of
vasodilation was shifted to larger vessels, which are the preferen-
tial site of endothelium-controlled vasodilation in our preparation
[46, 34].
URO effects on efferent arterioles after different pretreatments
were similar in the C and JM circulation except for URO effects
after CYOI (Figs. 2 and 4). After CYOI, URO significantly
constricted only C efferent arterioles, which could reflect the
specific role of prostaglandins in the female renal medullary
circulation. Blockade of NO synthesis amplified efferent vasocon-
striction at C and JM vessels.
Efferent vasoconstriction by URO was abolished after com-
bined ACE! and CYOI, after blockade of bradykinin B2
receptors, and after ET receptor blockade (Figs. 2 and 4).
These results, together with the observation that Ang II,
thromboxane, and a-adrenergic agonists are not involved in
efferent constriction mediated by URO [14, 20], strongly
suggest that the vascular endothelium of the efferent arteriole
is crucial in mediating constriction in response to URO.
Efferent vasoconstriction by URO is most probably mediated
by the secondary release of ET. The release of a constrictor,
through which URO acts on efferent arterioles, was assumed
on the basis of a greater latency in the onset of efferent
constriction compared with preglomerular dilation [10]. This
release of ET by URO could be modulated by kinins, prostag-
landins, and NO. Blockade of endothelial bradykinin B2 recep-
tors might interfere with URO by stimulation of endothelin
release, since GBF did not reach a stable state until 90 minutes
after the addition of the bradykinin antagonist. Many of the
biological effects of bradykinin are brought about by the
secondary release of other substances [53]. Since blockade of
NO synthesis enhances efferent constriction by URO, endothe-
hal release of NO may serve as a negative feedback. This could
be accomplished either by a shear stress-dependent release of
NO in the efferent arteriole or by stimulation of NO production
via endothelial ET receptors [54] or by a direct effect of URO
on NO production.
In summary, URO and ANF possess similar natriuretic and
identical vascular effects in normal and hydronephrotic rat kid-
neys, suggesting similar receptor binding and signal transduction
efficacy. Both peptides identically induce preglomerular vasodila-
tion and efferent constriction in the hydronephrotic kidney.
Preglomerular vasodilation, which is caused by receptor-mediated
activation of guanylate cyclase in vascular smooth muscle cells,
depends on the presence of endogenous vasoconstrictors. Efferent
vasoconstriction by natriuretic peptides might be the result of the
secondary release of endothelin, which could be modulated by
kinins, prostaglandins, and NO.
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